Molecular diagnostics and personalized medicine in oncology: Challenges and opportunities
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Molecular diagnostics and personalized medicine in oncology: Challenges and opportunities
Authors
Keywords
-
Journal
JOURNAL OF CELLULAR BIOCHEMISTRY
Volume 114, Issue 3, Pages 514-524
Publisher
Wiley
Online
2012-09-18
DOI
10.1002/jcb.24401
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Triple Negative Breast Cancer: From Molecular Portrait to Therapeutic Intervention
- (2012) Pietro Carotenuto et al. CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION
- ALK translocation and crizotinib in non-small cell lung cancer: An evolving paradigm in oncology drug development
- (2012) Giorgio Scagliotti et al. EUROPEAN JOURNAL OF CANCER
- Cancer Genomics: Technology, Discovery, and Translation
- (2012) Ben Tran et al. JOURNAL OF CLINICAL ONCOLOGY
- ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
- (2012) Kristin Bergethon et al. JOURNAL OF CLINICAL ONCOLOGY
- Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer
- (2012) Kang-Yi Su et al. JOURNAL OF CLINICAL ONCOLOGY
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
- (2012) Anirudh Prahallad et al. NATURE
- Chipping away at the lung cancer genome
- (2012) William Pao et al. NATURE MEDICINE
- RET, ROS1 and ALK fusions in lung cancer
- (2012) Kengo Takeuchi et al. NATURE MEDICINE
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- (2012) R. Katayama et al. Science Translational Medicine
- The Current State of Targeted Therapy in Melanoma: This Time It's Personal
- (2012) Keiran S.M. Smalley et al. SEMINARS IN ONCOLOGY
- Targeting Anaplastic Lymphoma Kinase in Lung Cancer
- (2011) A. T. Shaw et al. CLINICAL CANCER RESEARCH
- KIT as a Therapeutic Target in Metastatic Melanoma
- (2011) Richard D. Carvajal JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
- (2011) Masahiro Fukuoka et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Harboring BRAF Mutations
- (2011) Antonio Marchetti et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- BRAF targeted therapy changes the treatment paradigm in melanoma
- (2011) Antoni Ribas et al. Nature Reviews Clinical Oncology
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- KRAS Mutations Testing in Colorectal Carcinoma Patients in Italy: From Guidelines to External Quality Assessment
- (2011) Nicola Normanno et al. PLoS One
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- (2011) L. V. Sequist et al. Science Translational Medicine
- ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time
- (2010) David E. Gerber et al. CANCER CELL
- BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair
- (2010) P. J. O'Donovan et al. CARCINOGENESIS
- Predictive Biomarkers to Tyrosine Kinase Inhibitors for the Epidermal Growth Factor Receptor in Non-Small-Cell Lung Cancer
- (2010) A. De Luca et al. CURRENT DRUG TARGETS
- The biology and treatment of EML4-ALK non-small cell lung cancer
- (2010) Takaaki Sasaki et al. EUROPEAN JOURNAL OF CANCER
- Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
- (2010) Wendy De Roock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Clinical Implications of the Cancer Genome
- (2010) Laura E. MacConaill et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- Detection ofKRASmutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach
- (2010) Pietro Carotenuto et al. PHARMACOGENOMICS
- Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics
- (2009) B. T. Hennessy et al. CANCER RESEARCH
- Target-based therapies in breast cancer: current status and future perspectives
- (2009) Nicola Normanno et al. ENDOCRINE-RELATED CANCER
- Amphiregulin and Epiregulin mRNA Expression in Primary Tumors Predicts Outcome in Metastatic Colorectal Cancer Treated With Cetuximab
- (2009) Bart Jacobs et al. JOURNAL OF CLINICAL ONCOLOGY
- Implications for KRAS status and EGFR-targeted therapies in metastatic CRC
- (2009) Nicola Normanno et al. Nature Reviews Clinical Oncology
- Sequencing technologies — the next generation
- (2009) Michael L. Metzker NATURE REVIEWS GENETICS
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gene-Expression Signatures in Breast Cancer
- (2009) Christos Sotiriou et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular genetics of lung cancer in people who have never smoked
- (2008) Janakiraman Subramanian et al. LANCET ONCOLOGY
- Lung Cancer
- (2008) Roy S. Herbst et al. NEW ENGLAND JOURNAL OF MEDICINE
- Detection of Mutations inEGFRin Circulating Lung-Cancer Cells
- (2008) Shyamala Maheswaran et al. NEW ENGLAND JOURNAL OF MEDICINE
- KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program
- (2008) J. H. J. M. van Krieken et al. VIRCHOWS ARCHIV
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started